Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA9 | Q16790 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18855289 | 1.00 | SMN1; SMN2 (0.44) | SMN1; SMN2CA1CA9 | |
| SCHEMBL10024046 | 0.80 | SMN1; SMN2 (0.41) | SMN1; SMN2 | |
| SCHEMBL10046540 | 0.75 | — | — | |
| SCHEMBL8749613 | 0.73 | — | — | |
| SCHEMBL10345297 | 0.71 | SMN1; SMN2 (0.31) | SMN1; SMN2 | |
| SCHEMBL19085079 | 0.70 | — | — | |
| SCHEMBL12556352 | 0.69 | SMN1; SMN2 (0.31) | SMN1; SMN2 | |
| SCHEMBL10024065 | 0.68 | HMGCR (0.32) | — | |
| SCHEMBL433791 | 0.68 | HMGCR (0.32) | — | |
| SCHEMBL12650414 | 0.67 | SMN1; SMN2 (0.44) | SMN1; SMN2CA1CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8148550-B2 | selected from fluvastatin, rosuvastatin, cerivastatin, glenvastatin or atorvastatin, by reduction or lactonization of chemical intermediate compounds, then hydrogenation, decyclization and deprotection of hydroxy groups | RATIOPHARM GMBH (DE) | 2012-04-03 | — | — | US | disclosed |
| US-20080249306-A1 | Method for the Production of Statins | RATIOPHARM GMBH (DE) | 2008-10-09 | — | — | US | disclosed |
| US-20070093660-A1 | Method for the production of statins | RATIOPHARM GMBH (DE) | 2007-04-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070093660-A1 | Method for the production of statins | HMGCR, CYP11A1, CYP51A1 | SMN1; SMN2 3988/4885CA1 596/4885CA9 619/4885 |
| US-20080249306-A1 | Method for the Production of Statins | HMGCR, COASY, PCSK9 | SMN1; SMN2 4803/4885CA1 4113/4885CA9 1732/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.